Sun Pharmaceutical Industries Ltd., India’s largest pharma company that just announced the acquisition of US based Organon & Co for $ 11.75 billion, has always taken the acquisition route to drive growth within the country and outside. 

In its 42 years of operations, Sun Pharma has successfully carried out over two dozen acquisitions, big and small alike, across geographies to bolster its growth. This included acquisition of companies, business verticals, manufacturing facilities and products, Organon being the biggest one, so far.  

Sun Pharma made history when it acquired Ranbaxy Laboratories from Japanese drug major Daiichi Sankyo in 2014, thereby growing multifold in size and ranking within India and among generic drug companies, globally. Organon assets will similarly catapult Sun Pharma as one among the top 25 global pharmaceutical companies with combined revenue of $ 12.4 billion and a top 10 player globally in the biosimilars business.  

The company has been specifically focusing on the world’s largest pharma market US for its acquisitions in the past including ones like Caraco Pharma and US headquartered Israel company Taro, and recent ones like Concert Pharmaceuticals and Checkpoint Therapeutics. 

Here is a list of acquisitions carried out by Sun Pharma over the years: 

2026 – Announced acquisition of Organon, USA 

2025 - Acquired Checkpoint Therapeutics in USA 

2023 - Acquired Concert Pharmaceuticals in USA 

2022 - Acquired Uractiv portfolio from Fiterman Pharma in Romania 

2019 - Acquired Pola Pharma in Japan to strengthen global dermatology presence 

2016 - Acquired 14 brands from Novartis in Japan, acquired Ocular Technologies, Sarl to strengthen branded ophthalmic portfolio, acquired Biosintez to enhance presence in Russian market 

2015 - Acquired GSK’s Opiates business in Australia, acquired InSite Vision Inc. to strengthen branded ophthalmic portfolio in USA 

2014 - Acquired Indian drug major Ranbaxy, Pharmalucence in USA 

2012 - Acquired Dusa Pharmaceuticals and the generic business of URL Pharmaceuticals in USA 

2010 - Acquired controlling stake in Israel-based Taro Pharmaceuticals, headquartered in USA to effectively double company’s US business 

2008 - Acquired Chattem Chemicals Inc, USA 

2005 - Completed buyout of manufacturing unit in Bryan, Ohio, USA, acquired ICN’s business in Hungary from Valeant Pharma 

2004 – Acquired Phlox Pharma (India) and niche brands from Women’s First Healthcare (USA) 

1999 – Acquired Milmet Labs, Cephalexin and 7ADCA actives manufacturing site in India 

1997 – Acquired stake in Caraco Pharma (acquired 100% stake in 2010) 

1996 – Acquired active pharmaceutical ingredient manufacturing plant from Knoll Pharma.